Trade Now

Capital at risk Advertisement
Share Name Share Symbol Market Type Share ISIN Share Description
Syncona Limited LSE:SYNC London Ordinary Share GG00B8P59C08 ORD NPV
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.20 -0.12% 160.00 159.00 159.80 161.00 159.00 159.40 377,269 12:52:31
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Equity Investment Instruments 25.4 15.5 2.3 68.4 1,071

Syncona Share Discussion Threads

Showing 18826 to 18848 of 18900 messages
Chat Pages: 756  755  754  753  752  751  750  749  748  747  746  745  Older
DateSubjectAuthorDiscuss
02/8/2021
22:08
is this the reason for today's rise? htTps://www.fiercebiotech.com/biotech/moderna-lands-option-autolus-binders-to-fuel-oncology-plans
davemac3
16/7/2021
11:56
John Rosier mentions Syncona (SYNC) in the latest PIWORLD interview at 12m14s Watch the video here: Https://www.piworld.co.uk/education-videos/piworld-interview-john-rosiers-portfolio-update-july-2021/ Or listen to the podcast here: Https://piworld.podbean.com/e/piworld-interview-john-rosiers-portfolio-update-july-2021/
tomps2
24/6/2021
19:09
SYNC sinking further. Why so negative?
1seanshare
21/5/2021
11:01
Depends how you want to look at it. CAR-T sales are probably growing 40-80% per year at the moment, with a substantial number of trials with people like Autolus. Heck, Autolus are even on the lower end of the risk/safety profile, so they have some 1st mover advantages there. Although I am not clear how Autolus will scale long term. CAR-T are not simple processes.
luxaeterna1
13/5/2021
15:52
htTps://www.fiercebiotech.com/biotech/autolus-cd19-car-t-posts-100-complete-response-rate-zero-grade-3-crs-small-lymphoma-trial
davemac3
13/5/2021
15:27
T Henderson, check director rns.
chc15
13/5/2021
10:16
Yes that's correct. My concern is about CAR-Ts in general. They aren't the be all they were promised to be, there is considerable toxicity for patients who are already heavily pretreated, and they are very complex and onerous to deliver. It could be that CAR-Ts in general are not being used as much as first envisaged
1seanshare
13/5/2021
09:31
Am I correct, that iNHL is basically slow growing lymphoma, so a 100% complete response rate (in phase 1), would be indicative that Autolus CARs being used at earlier stages?
luxaeterna1
12/5/2021
23:09
As you say 1seanshare "that's welcome", may be you should have said Welcome :-)a very aristocratic organisation which has had tremendous power but with whom I have mixed feelings in the modern competitive market. Maybe past its heyday.
mayers
12/5/2021
20:09
iNHL results go BOOM for Autolus.
luxaeterna1
12/5/2021
14:01
Which one, where do you see that? Is the price drop not an over reaction to gyroscope delay?
1seanshare
12/5/2021
13:33
Director dumping loads.
chc15
11/5/2021
13:10
Sold out a while ago and been watching from the sidelines. Tempted to jump back in but I’d prefer to see a change in fortunes. Even since the poor Q1 figs to 31st March, Autolus down 16%, Freeline down 25% and Gyroscope IPO announced and pulled. Not good.
acuere
11/5/2021
09:08
It is odd. I suspect they meant it was simply due to covid-related uncertainty, which meant an unacceptable pricing offer. Although Gyroscope (long term eye health) may operate on a longer timeframe than your average IPO and that might discourage investors. Interesting to see if they wait 6-9 months, or look at Syncona/3rd party private partnership. Ha, oh wait, I just re-read the RNS, it does look quite silly having a 4-day delay between the RNS announcing and then postponing it doesn't it? I'm sure they cringed at that. On the other hand, a good drop in sentiment like this, could actually be a solid entry position if you believe in the long-term prospects of SYNC, & in particular Autolus.
luxaeterna1
07/5/2021
08:39
Beginning to think I made a mistake getting into this. To announce an IPO and then decide only a couple of weeks later that you are pulling it "due to market conditions" makes management look incompetent!
salpara111
06/5/2021
19:56
What on earth happened to Freeline today? At one point it was down 25%. SYNC being held back by Freeline and Autolus?
1seanshare
18/4/2021
11:05
What do you guys think about the recent Autolus decision to focus manufacture on the UK plant? I suppose cashflow has been tight, so they are trying to avoid initial capex, on a facility that I asusme would take significant staff qty, training, QA and approvals etc. In my head, it doesn't seem that it would grossly affect logistics by having to ship to UK instead (package deliveries can be overnight from major cities, so frankly it would take overnight to get domestic shipments done). Overall, I see it as a positive development for the UK staff and getting things rolling. Perhaps when they have significant cash revenues they can look at expansion. Does anyone know what the ultimate Autolus target market is? Initial treatments in EU/US could show ~ 20k patients per year, but this could become a significantly higher figure if they get more approved treatments. Between the various genetic treatments being presented by the wider Syncona group, you could argue that number starts to become millions in 10 years time.
luxaeterna1
15/4/2021
14:47
I'd set a cheeky limit order to buy at 232 a week ago and just got notification that it had been executed. I cant see any specific reason for the big drop today so I guess I am happy to be on board at that price.
salpara111
13/4/2021
11:43
I've halved my holding here and reinvested in Oakley Capital.
brexitplus
05/2/2021
07:43
Interesting positive news from Achilles today. Moderate signs of efficacy at very low mono dosing. Higher doses and combination therapies.
luxaeterna1
28/1/2021
15:30
Is there any obvious reason for the drop in SYNC over the last week - is it all down to AUTOLUS and FREELINE?
1seanshare
17/12/2020
16:15
A remarkable number of buys of 1 and 2 shares today. I wonder why? Perhaps that's the reason the share price has improved so much. I'd buy in small amounts like that if the share price zoomed up but my broker charges too much. Going back to basics it is clear to me that the parts of SYNC are undervalued and that we are overdue an substantial upward appreciation.
chessman2
17/12/2020
15:35
I got in at £1.70 but I think there’s a bit to go. I suspect a big pharma will buy Autolus to gain a CAR-T
1seanshare
Chat Pages: 756  755  754  753  752  751  750  749  748  747  746  745  Older
ADVFN Advertorial
Your Recent History
LSE
SYNC
Syncona
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20220929 12:25:44